文献速递脊柱关节炎

银屑病关节炎患者对生物制剂治疗偏好的离散选择实验

Preferences for Biologic Treatment in Patients With Psoriatic Arthritis: A Discrete Choice Experiment.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-06-01

该研究在澳大利亚悉尼3个风湿病中心对150例银屑病关节炎患者进行离散选择实验,评估其对生物制剂和靶向合成DMARDs属性与结局的偏好。结果显示患者最偏好口服给药,其次为避免严重副作用、维持正常活动能力和避免感染,这些因素优先于疗效指标。

要点

  • 银屑病关节炎患者选择生物制剂时最偏好口服给药途径。
  • 避免严重副作用和维持正常活动能力优先于关节痛改善等疗效指标。
  • 避免感染的重要性高于关节痛、附着点炎和银屑病改善。

核心结论

  • 银屑病关节炎患者选择生物制剂时偏好口服药物,并将避免严重并发症、维持工作与正常活动能力及避免感染置于临床疗效指标之上。

研究设计与样本

  • 在澳大利亚悉尼3个风湿病中心对150例银屑病关节炎患者开展的离散选择实验。
  • 评估生物制剂不同属性的偏好,给药途径和频率设5个水平,其余7个属性各设3个水平。
  • 采用多项logit模型(包括潜在类别模型)计算偏好。

主要发现

  • 150例参与者中58.3%为女性,中位年龄53.5岁。
  • 按β系数绝对值排序,口服途径相对于皮下和静脉途径的β系数为1.00(固定参数)。
  • 避免严重副作用的β系数为0.72(95%CI 0.50, 0.95)。
  • 提高参加正常活动能力的β系数为0.66(95%CI 0.36, 0.96)。
  • 避免感染的β系数为0.38(95%CI 0.23, 0.53);改善附着点炎疼痛和改善银屑病的β系数均为0.28(95%CI 0.20, 0.36);提高缓解机会的β系数为0.27(95%CI 0.19, 0.36);改善关节痛的β系数为0.26(95%CI 0.00, 0.52)。

临床怎么用

  • 与银屑病关节炎患者讨论生物制剂选择时,应优先考虑口服给药方案的可及性。
  • 沟通中需重点说明严重副作用和感染风险,以及治疗对维持正常活动能力的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to assess patient preferences for the characteristics and outcomes of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) to manage psoriatic arthritis. METHODS: We conducted a discrete choice experiment in patients with psoriatic arthritis from 3 rheumatology centers in Sydney, Australia. We assessed preferences for different attributes of biologic medications. The route and frequency of medications had a range of 5 levels, and the following 7 attributes had a range of 3 levels: the ability to attend to normal activities, improvements in joint pain, enthesitis and skin disease, chance of disease remission, risk of infection, and risk of severe adverse events. Multinomial logit models including a latent class model were used to calculate preferences. RESULTS: Of the 150 participants, 58.3% were female, with a median age of 53.5 years. The attributes in order of preference using the β coefficient in absolute values (95% confidence interval [95% CI]) were as follows: oral route compared to subcutaneous and intravenous routes (β coefficient 1.00 [fixed parameter]), avoiding severe side effects (β coefficient 0.72 [95% CI 0.50, 0.95]), increasing ability to attend to normal activities (β coefficient 0.66 [95% CI 0.36, 0.96]), avoiding infections (β coefficient 0.38 [95% CI 0.23, 0.53]), improvement in enthesitis pain (β coefficient 0.28 [95% CI 0.20, 0.36]), improvement in psoriasis (β coefficient 0.28 [95% CI 0.20, 0.36]), increasing chance of remission (β coefficient 0.27 [95% CI 0.19, 0.36]), and improvement in joint pain (β coefficient 0.26 [95% CI 0.00, 0.52]). CONCLUSION: When choosing biologic medications, patients with psoriatic arthritis preferred oral medications. Patients prioritized avoiding severe complications, maintaining the ability to attend to work and normal activities, and avoiding infection over clinical measures of efficacy.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Sumpton D, Kelly A, Craig JC, et al. Preferences for Biologic Treatment in Patients With Psoriatic Arthritis: A Discrete Choice Experiment. Arthritis Care Res (Hoboken). 2022. PMID: 34514744. doi:10.1002/acr.24782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。